Who is sponsoring NCT03986385?

NCT03986385 is sponsored by Hebei Medical University.

What drugs are being tested in NCT03986385?

Interventions in NCT03986385: Apatinib Capecitabine Oxaliplatin, Capecitabine Oxaliplatin.

What condition does NCT03986385 study?

NCT03986385 studies Gastroesophageal Junction Adenocarcinoma.

Is NCT03986385 still recruiting?

NCT03986385 is currently status unknown. Last updated 19 February 2020.

Last reviewed 2020-02-19 · How we verify

NCT03986385

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction

Status unknown Phase 3 Last updated 19 February 2020

What this trial tests

Phase 3 trial testing Apatinib Capecitabine Oxaliplatin in Gastroesophageal Junction Adenocarcinoma in 180 participants. Status unknown.

Timeline

1 June 2019

Primary endpoint
30 June 2020

31 January 2021

Quick facts

Lead sponsor	Hebei Medical University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	180
Start date	1 June 2019
Primary completion	30 June 2020
Estimated completion	31 January 2021
Sites	1 location across China

Drugs / interventions tested

Apatinib Capecitabine Oxaliplatin — full drug profile →
Capecitabine Oxaliplatin

Conditions studied

Gastroesophageal Junction Adenocarcinoma — all drugs for Gastroesophageal Junction Adenocarcinoma →

Sponsor

Hebei Medical University

Who can join

Adults 18 to 70, any sex, with Gastroesophageal Junction Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gastroesophageal Junction Adenocarcinoma

Currently open trials in the same condition.

NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07311408 — SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure · Phase 2 · recruiting
NCT07182565 — Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcin · Phase 1, PHASE2 · recruiting
NCT07179484 — To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric · recruiting
NCT07072351 — Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Ade · Phase 1, PHASE2 · recruiting

Other Hebei Medical University trials

Trials by the same sponsor.

NCT07304258 — A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cance · Phase 2 · not yet recruiting
NCT06934824 — Clinical Study of Double-Endoscopic Combined With Minimally Invasive Treatment for Early Gastric Cancer at Clinical Stag · NA · not yet recruiting
NCT06534814 — Development and Application of an Artificial Intelligence-driven Accurate Identification Model for Gastric Cancer Lymph · recruiting
NCT06201585 — Exploratory Study of Single-port Robot-assisted Gastrectomy · NA · unknown
NCT06073483 — Exploratory Study of Toumai Endoscopic Surgery System for Remote Gastrectomy · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03986385 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hebei Medical University
Last refreshed: 19 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03986385.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing